MPM BioImpact

Investing
in the Future
of Medicine

We invest in private and public companies across the drug development process with the goal of transforming scientific breakthroughs into life saving medicines.

LEARN MORE

30+ Years of Biotech Investing

60 FDA-approved drugs

120+ M&A and IPO events

We Build and Support Companies that Transform Patient Outcomes

We built Aktis Oncology to realize the transformative potential of alpha radio-pharmaceuticals for patients with solid tumors.

Aktis is pioneering miniprotein actinium-conjugates to deliver breakthrough efficacy and enhanced safety compared to earlier generations of radiopharmaceuticals, while treating a broader set of cancer patients beyond prostate and neuroendocrine tumors.

VISIT THE Aktis SITE

Scientific illustration depicting Aktis’ selective tumor-targeting radiopharmaceuticals penetrating tumors.

We built Orna Therapeutics to create a new class of coding RNA medicines that outperforms mRNA.

Orna’s circular RNA technology (oRNA) and best-in-class non-viral delivery are fundamentally changing the landscape of treatment modalities,^* starting with replacing cell therapies in autoimmune diseases and oncology indications.

In 2026, Orna was acquired by Lilly for up to $2.4 billion.

VISIT THE ORNA SITE

We backed Reunion’s world-class team of experienced neuroscience drug developers in their efforts to revolutionize the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired novel pharmaceutical compounds with composition of matter IP.

Reunion is developing a potential best-in-class, short duration 5-HT2AR agonist for patients with postpartum depression, adjustment disorder and generalized anxiety disorder.

VISIT THE REUNION SITE

We were early supporters of argenx, which has since emerged as one of the most successful biotechnology companies in history and a global leader in immunology.

argenx pioneered and now markets the first approved neonatal Fc receptor (FcRn) blocker VYVGART, making a meaningful impact across multiple serious autoimmune diseases. In addition, argenx continues to advance a robust pipeline of early-stage therapies across autoimmune diseases.

VISIT THE ARGENX SITE

“Aktis was founded at MPM BioImpact with an ambitious vision to transform the radiopharmaceutical field. The team at MPM BioImpact has lent significant leadership, expertise, and support to enable Aktis to realize this significant patient impact potential.”*

Matthew Roden, Ph.D.

Matthew Roden, Ph.D.

Chief Executive Officer

Todd Foley

Chairman

In the News

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Aktis Oncology Initiates Phase 1b Clinical Trial Of Its Nectin-4- Targeting Radiopharmaceutical Product Candidate, Aky-1189, Across Multiple Tumor Types

*Quotes are provided for the purpose of recruiting executives and academics to partner with MPM BioImpact. The quotes are provided by individuals who have a business and/or economic relationship with MPM BioImpact, and are not intended to solicit or offer investment advisory services.

"We are proud to have created and built Orna based on groundbreaking research that came out of MIT. Orna is combining its proprietary circular RNA platform with industry leading delivery technology to create transformative medicines using the panCAR approach.”**

Ansbert Gadicke, M.D.

Ansbert Gadicke, M.D.

Former Chairman

Joseph Bolen, Ph.D.

Former CEO and MPM Entrepreneur Partner

Frank Neumann, M.D., Ph.D.

Former Chief Medical Officer

In the News

Lilly to Acquire Orna Therapeutics to Advance Cell Therapies

Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

*Garber, K., "Orna Therapeutics: circular logic," Nature Biotechnology, 05 August 2022, https://doi.org/10.1038/d41587-022-00005-1

**Quotes are provided for the purpose of recruiting executives and academics to partner with MPM BioImpact. The quotes are provided by individuals who have a business and/or economic relationship with MPM BioImpact, and are not intended to solicit or offer investment advisory services.

“We are proud to support Reunion, a company pioneering a new treatment paradigm for severe mental health disorders. The impressive Phase 2 clinical data in postpartum depression (PPD) support the lead program’s unique profile and reinforce its potential to transform the treatment landscape across multiple severe indications.”*

Ansbert Gadicke, M.D.

Ansbert Gadicke, M.D.

CHAIRMAN

In the News

U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status

Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)

Reunion Neuroscience | Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)

“MPM BioImpact was an early public investor in argenx, after identifying the potential of its lead drug Vyvgart to address a shared underlying pathology across multiple autoimmune diseases. With Vyvgart now recognized as one of the most successful drug launches in industry history, we’re proud to see our early investment thesis validated and, even more so, to see the drug improving the lives of thousands of patients with autoimmune disorders.”*

Chris Bardon, M.D.

Chris Bardon, M.D.

MANAGING PARTNER

In the News

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

Meet our Team

MPM BioImpact’s investment team consists of professionals who have dedicated their careers to research and drug development, company creation, corporate strategy, and commercialization. This includes our Entrepreneur Partners, who provide deep domain expertise in the most innovative areas of biotechnology, capabilities across the entire drug development process, and a track record of navigating the complex regulatory landscape. We are a team of deeply experienced industry experts who help transform scientific discoveries into breakthrough medicines for the patients that need them most.

Learn about our team of experts